Kairos Pharma Files 8-K
Ticker: KAPA · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1962011
Sentiment: neutral
Topics: 8-K, regulatory-filing
TL;DR
Kairos Pharma filed an 8-K, likely for routine updates or exhibit filings.
AI Summary
On June 3, 2025, Kairos Pharma, Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," with no specific material events or financial figures detailed in the provided excerpt. The company is incorporated in Delaware and its principal executive offices are located in Los Angeles, California.
Why It Matters
This 8-K filing indicates that Kairos Pharma, Ltd. is making a regulatory submission, which could precede significant announcements or updates regarding its financial status or business operations.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant positive or negative events.
Key Players & Entities
- Kairos Pharma, Ltd. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- 2355 Westwood Blvd. , #139 Los Angeles CA 90064 (location) — Address of principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Kairos Pharma, Ltd.?
The filing indicates it covers 'Other Events' and 'Financial Statements and Exhibits', suggesting it may be for routine updates or the submission of supporting documents.
When was the earliest event reported in this filing?
The earliest event reported is dated June 3, 2025.
Where are Kairos Pharma, Ltd.'s principal executive offices located?
The principal executive offices are located at 2355 Westwood Blvd., #139, Los Angeles, CA 90064.
What is the state of incorporation for Kairos Pharma, Ltd.?
Kairos Pharma, Ltd. is incorporated in Delaware.
What is the telephone number provided for Kairos Pharma, Ltd.?
The registrant's telephone number, including area code, is (310) 948-2356.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Kairos Pharma, LTD. (KAPA).